Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for 
Non-small Cell Lung Cancer

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for 
Non-small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors, especially programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have made a breakthrough in the treatment of N...

Full description

Bibliographic Details
Main Authors: Sixuan WU, Chunhong HU, Fang WU, Yuanqiang WU, Ping LIU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2019-07-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Cancer immunotherapy
PD-1/PD-L1
Immune checkpoint inhibitor
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2019.07.06

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2019.07.06

Similar Items